We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+25.88%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$7.99B
AUM Growth
+$1.36B
Cap. Flow
+$167M
Cap. Flow %
2.09%
Top 10 Hldgs %
82.62%
Holding
149
New
30
Increased
33
Reduced
21
Closed
40

Top Buys

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$40.6M
2
TSRO
TESARO, Inc.
TSRO
+$32.2M
3
BPMC
Blueprint Medicines
BPMC
+$30.2M
4
NKTR icon
Nektar Therapeutics
NKTR
+$25.8M
5
FOLD
Amicus Therapeutics
FOLD
+$22.8M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$21.1M
2
INCY icon
Incyte
INCY
+$18M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$8.37M
4
CLVS
Clovis Oncology, Inc.
CLVS
+$5.83M
5
ALDR
Alder Biopharmaceuticals
ALDR
+$5.72M

Sector Composition

Rank Sector Weight
1 Consumer Staples 43.57%
2 Consumer Discretionary 23.48%
3 Healthcare 17.53%
4 Communication Services 0.15%
5 Materials 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LJPC
51
DELISTED
La Jolla Pharmaceutical Company
LJPC
$8.93M 0.11%
+300,000
New +$9.67M
DNLI icon
52
Denali Therapeutics
DNLI
$3.79B
$8.86M 0.11%
450,000
-50,000
-10% -$1.03M
TSRO
53
CALL
DELISTED
TESARO, Inc.
TSRO
$8.57M 0.11%
150,000
+125,000
+500% +$8.04M
FATE icon
54
Fate Therapeutics
FATE
$275M
$8.3M 0.1%
+850,000
New +$8.14M
NBIX icon
55
CALL
Neurocrine Biosciences
NBIX
$18.2B
$8.29M 0.1%
+100,000
New +$8.44M
ZGNX
56
DELISTED
Zogenix, Inc.
ZGNX
$8.01M 0.1%
+200,000
New +$7.93M
IOVA icon
57
Iovance Biotherapeutics
IOVA
$2.04B
$7.77M 0.1%
+460,000
New +$6.97M
RGNX icon
58
Regenxbio
RGNX
$616M
$7.46M 0.09%
250,000
– –
IMUX icon
59
Immunic
IMUX
$178M
$6.8M 0.09%
2,500
+312
+14% +$716K
MDCO
60
DELISTED
Medicines Co
MDCO
$6.59M 0.08%
200,000
– –
ACIU icon
61
AC Immune
ACIU
$231M
$6.2M 0.08%
600,000
+100,000
+20% +$1.22M
STML
62
DELISTED
Stemline Therapeutics, Inc.
STML
$6.12M 0.08%
400,000
+200,000
+100% +$3.12M
WVE icon
63
Wave Life Sciences
WVE
$1.12B
$6.01M 0.08%
150,000
+57,922
+63% +$2.43M
PRQR icon
64
ProQR Therapeutics
PRQR
$244M
$5.84M 0.07%
1,900,000
– –
CBIO
65
Crescent Biopharma
CBIO
$546M
$5.28M 0.07%
3,250
+750
+30% +$1.56M
MDGL icon
66
Madrigal Pharmaceuticals
MDGL
$12.6B
$5.26M 0.07%
+45,000
New +$5.55M
CBAY
67
DELISTED
Cymabay Therapeutics
CBAY
$5.2M 0.07%
+400,000
New +$4.97M
KDNY
68
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$5.12M 0.06%
110,000
+70,000
+175% +$2.56M
ACGN
69
DELISTED
Aceragen Inc
ACGN
$5.06M 0.06%
+20,241
New +$5.55M
SPRO icon
70
Spero Therapeutics
SPRO
$68.9M
$4.99M 0.06%
350,000
– –
DVAX
71
CALL
DELISTED
Dynavax Technologies
DVAX
$4.96M 0.06%
+250,000
New +$4.32M
RCKT icon
72
Rocket Pharmaceuticals
RCKT
$343M
$4.69M 0.06%
+250,000
New +$4.08M
RCUS icon
73
Arcus Biosciences
RCUS
$3.33B
$4.63M 0.06%
+300,000
New +$5M
BPMC
74
CALL
DELISTED
Blueprint Medicines
BPMC
$4.58M 0.06%
+50,000
New +$4.31M
AKBA icon
75
Akebia Therapeutics
AKBA
$338M
$4.53M 0.06%
+475,000
New +$6.64M
1 2
3
4 5

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2018 Portfolio in Review

As of Q1 2018, Artal Group held 149 positions worth $7.99B, up 21% from $6.63B the previous quarter. Its ten largest holdings account for 83% of the portfolio.

Artal Group's Q1 2018 filing shows 30 new, 33 increased, 21 reduced and 40 closed positions. Its largest new stake was Kyntra Bio: 10,000 shares worth $11.6M. The largest sale was Neurocrine Biosciences, an estimated $21.1M.

By sector, the portfolio is most concentrated in Consumer Staples at 44% of assets, up from 43% a quarter earlier, followed by Consumer Discretionary and Healthcare.

  • Artal Group's largest Q1 2018 buy was Kyntra Bio: 10,000 shares worth $11.6M.
  • Artal Group added most to BeOne Medicines Ltd in Q1 2018, an estimated $40.6M increase.
  • Artal Group's biggest Q1 2018 reduction was Incyte, cutting an estimated $18M.
  • Artal Group fully exited Neurocrine Biosciences in Q1 2018, selling an estimated $21.1M.
  • Artal Group's ten largest holdings make up 83% of its $7.99B portfolio in Q1 2018.
  • Artal Group opened 30 new positions and closed 40 in Q1 2018.
  • Artal Group's portfolio value rose 21% quarter-over-quarter to $7.99B.

Based on Artal Group's 13F filing for Q1 2018, filed 10 May 2018.